<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380730</url>
  </required_header>
  <id_info>
    <org_study_id>20101155</org_study_id>
    <nct_id>NCT01380730</nct_id>
  </id_info>
  <brief_title>LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy</brief_title>
  <acronym>LAPLACE</acronym>
  <official_title>LAPLACE TIMI 57 - A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With HMG-CoA Reductase Inhibitors in Hypercholesterolemic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TIMI Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered
      every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from
      baseline in LDL-C when used in addition to a statin in adults with hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LDL-C was measured using ultracentrifugation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LDL-C was measured using ultracentrifugation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">631</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 70 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 105 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 140 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 280 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 350 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 420 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Evolocumab 70 mg Q2W</arm_group_label>
    <arm_group_label>Evolocumab 105 mg Q2W</arm_group_label>
    <arm_group_label>Evolocumab 140 mg Q2W</arm_group_label>
    <arm_group_label>Evolocumab 280 mg Q4W</arm_group_label>
    <arm_group_label>Evolocumab 350 mg Q4W</arm_group_label>
    <arm_group_label>Evolocumab 420 mg Q4W</arm_group_label>
    <other_name>AMG 145</other_name>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 80 years of age

          -  On an approved statin, with or without ezetimibe, with stable dose(s) for at least 4
             weeks

          -  Fasting LDL-C ≥ 85 mg/dL

          -  Fasting triglycerides ≤ 400 mg/dL

        Exclusion Criteria:

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
             coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization

          -  Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes (Glycosyated
             Hemoglobin (HbA1c) &gt; 8.5%)

          -  Uncontrolled hypertension

          -  New York Heart Association (NYHA) III or IV heart failure, or known left ventricular
             ejection fraction &lt; 30%

          -  Uncontrolled cardiac arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malvern</city>
        <state>Arkansas</state>
        <zip>72104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Green Cove Springs</city>
        <state>Florida</state>
        <zip>32043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hammond</city>
        <state>Indiana</state>
        <zip>46320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <zip>49855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cortlandt Manor</city>
        <state>New York</state>
        <zip>10567</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smithfield</city>
        <state>North Carolina</state>
        <zip>27577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <zip>29501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V5G 1T4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P 2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3C 5K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M8V 3X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lachine</city>
        <state>Quebec</state>
        <zip>H8S 2E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <zip>J4N 0C9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>603 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Svitavy</city>
        <zip>568 25</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Usti nad Orlici</city>
        <zip>562 18</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Znojmo</city>
        <zip>669 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dunaujvaros</city>
        <zip>2400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Komarom</city>
        <zip>2991</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szolnok</city>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012 Dec 8;380(9858):2007-17. doi: 10.1016/S0140-6736(12)61770-X. Epub 2012 Nov 6.</citation>
    <PMID>23141813</PMID>
  </reference>
  <reference>
    <citation>Kohli P, Desai NR, Giugliano RP, Kim JB, Somaratne R, Huang F, Knusel B, McDonald S, Abrahamsen T, Wasserman SM, Scott R, Sabatine MS. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2012;35(7):385-91. doi: 10.1002/clc.22014. Epub 2012 Jun 19.</citation>
    <PMID>22714699</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>September 1, 2015</results_first_submitted>
  <results_first_submitted_qc>September 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2015</results_first_posted>
  <disposition_first_submitted>March 26, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 2, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 9, 2013</disposition_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Proprotein convertase subtilisin/kexin type 9 (PCSK9)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study enrolled adults aged 18 - 80 years who were on a statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks, and fasting low-density lipoprotein cholesterol (LDL-C) ≥ 85 mg/dL.
The first patient enrolled on 18 July 2011 and the last patient enrolled on 22 December 2011.</recruitment_details>
      <pre_assignment_details>Eligible participants were randomized equally into 1 of 8 treatment groups. Randomization was stratified by screening LDL-C level (&lt; 130 mg/dL or ≥ 130 mg/dL) and ezetimibe use at baseline (yes or no).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Q4W</title>
          <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Evolocumab 70 mg Q2W</title>
          <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Evolocumab 105 mg Q2W</title>
          <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Evolocumab 280 mg Q4W</title>
          <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Evolocumab 350 mg Q4W</title>
          <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Evolocumab 420 mg Q4W</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="78"/>
                <participants group_id="P6" count="79"/>
                <participants group_id="P7" count="79"/>
                <participants group_id="P8" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="77">2 participants did not receive treatment but were followed until the end of study</participants>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="78"/>
                <participants group_id="P6" count="79"/>
                <participants group_id="P7" count="79"/>
                <participants group_id="P8" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="77"/>
                <participants group_id="P6" count="79"/>
                <participants group_id="P7" count="79"/>
                <participants group_id="P8" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (all randomized participants who received at least 1 dose of investigational product).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Q4W</title>
          <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Evolocumab 70 mg Q2W</title>
          <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Evolocumab 105 mg Q2W</title>
          <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Evolocumab 280 mg Q4W</title>
          <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Evolocumab 350 mg Q4W</title>
          <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Evolocumab 420 mg Q4W</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="79"/>
            <count group_id="B4" value="79"/>
            <count group_id="B5" value="78"/>
            <count group_id="B6" value="79"/>
            <count group_id="B7" value="79"/>
            <count group_id="B8" value="80"/>
            <count group_id="B9" value="629"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="8.8"/>
                    <measurement group_id="B2" value="60.1" spread="9.6"/>
                    <measurement group_id="B3" value="59.4" spread="9.9"/>
                    <measurement group_id="B4" value="58.8" spread="9.7"/>
                    <measurement group_id="B5" value="62.4" spread="10.2"/>
                    <measurement group_id="B6" value="60.3" spread="8.4"/>
                    <measurement group_id="B7" value="61.9" spread="8.8"/>
                    <measurement group_id="B8" value="60.9" spread="10.3"/>
                    <measurement group_id="B9" value="60.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="38"/>
                    <measurement group_id="B8" value="44"/>
                    <measurement group_id="B9" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="41"/>
                    <measurement group_id="B8" value="36"/>
                    <measurement group_id="B9" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="67"/>
                    <measurement group_id="B6" value="64"/>
                    <measurement group_id="B7" value="72"/>
                    <measurement group_id="B8" value="70"/>
                    <measurement group_id="B9" value="558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="72"/>
                    <measurement group_id="B6" value="78"/>
                    <measurement group_id="B7" value="79"/>
                    <measurement group_id="B8" value="78"/>
                    <measurement group_id="B9" value="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: LDL-C Level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 130 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="51"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="53"/>
                    <measurement group_id="B9" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 130 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Baseline Ezetimibe Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="72"/>
                    <measurement group_id="B7" value="72"/>
                    <measurement group_id="B8" value="73"/>
                    <measurement group_id="B9" value="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C Concentration</title>
          <description>LDL-C was measured using ultracentrifugation.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122.2" spread="27.1"/>
                    <measurement group_id="B2" value="124.9" spread="30.6"/>
                    <measurement group_id="B3" value="121.4" spread="24.4"/>
                    <measurement group_id="B4" value="127.4" spread="32.1"/>
                    <measurement group_id="B5" value="120.9" spread="25.1"/>
                    <measurement group_id="B6" value="122.0" spread="28.8"/>
                    <measurement group_id="B7" value="123.2" spread="27.1"/>
                    <measurement group_id="B8" value="120.8" spread="26.5"/>
                    <measurement group_id="B9" value="122.8" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146.9" spread="29.9"/>
                    <measurement group_id="B2" value="150.2" spread="36.5"/>
                    <measurement group_id="B3" value="145.3" spread="29.9"/>
                    <measurement group_id="B4" value="151.2" spread="37.2"/>
                    <measurement group_id="B5" value="145.3" spread="26.2"/>
                    <measurement group_id="B6" value="146.3" spread="33.3"/>
                    <measurement group_id="B7" value="150.0" spread="29.1"/>
                    <measurement group_id="B8" value="144.4" spread="31.2"/>
                    <measurement group_id="B9" value="147.4" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.9" spread="17.0"/>
                    <measurement group_id="B2" value="101.6" spread="20.0"/>
                    <measurement group_id="B3" value="99.9" spread="16.8"/>
                    <measurement group_id="B4" value="103.6" spread="22.3"/>
                    <measurement group_id="B5" value="98.8" spread="16.6"/>
                    <measurement group_id="B6" value="101.3" spread="21.2"/>
                    <measurement group_id="B7" value="102.6" spread="18.9"/>
                    <measurement group_id="B8" value="99.9" spread="18.6"/>
                    <measurement group_id="B9" value="100.9" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol/HDL-C ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.940" spread="1.016"/>
                    <measurement group_id="B2" value="4.057" spread="1.303"/>
                    <measurement group_id="B3" value="4.002" spread="1.243"/>
                    <measurement group_id="B4" value="4.128" spread="1.473"/>
                    <measurement group_id="B5" value="3.932" spread="1.022"/>
                    <measurement group_id="B6" value="4.007" spread="1.300"/>
                    <measurement group_id="B7" value="4.118" spread="0.963"/>
                    <measurement group_id="B8" value="3.885" spread="1.090"/>
                    <measurement group_id="B9" value="4.008" spread="1.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B/Apolipoprotein A-1 Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.660" spread="0.155"/>
                    <measurement group_id="B2" value="0.676" spread="0.194"/>
                    <measurement group_id="B3" value="0.675" spread="0.191"/>
                    <measurement group_id="B4" value="0.695" spread="0.219"/>
                    <measurement group_id="B5" value="0.649" spread="0.155"/>
                    <measurement group_id="B6" value="0.662" spread="0.199"/>
                    <measurement group_id="B7" value="0.687" spread="0.175"/>
                    <measurement group_id="B8" value="0.653" spread="0.177"/>
                    <measurement group_id="B9" value="0.670" spread="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <description>LDL-C was measured using ultracentrifugation.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing ultracentrifugation LDL-C at Week 12 was imputed using last observation carried forward (LOCF) and calculated LDL-C.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <description>LDL-C was measured using ultracentrifugation.</description>
          <population>Full analysis set; missing ultracentrifugation LDL-C at Week 12 was imputed using last observation carried forward (LOCF) and calculated LDL-C.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="79"/>
                <count group_id="O8" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="2.39"/>
                    <measurement group_id="O2" value="-0.98" spread="2.51"/>
                    <measurement group_id="O3" value="-39.06" spread="2.39"/>
                    <measurement group_id="O4" value="-57.48" spread="2.39"/>
                    <measurement group_id="O5" value="-63.34" spread="2.40"/>
                    <measurement group_id="O6" value="-42.82" spread="2.52"/>
                    <measurement group_id="O7" value="-50.98" spread="2.51"/>
                    <measurement group_id="O8" value="-51.31" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-66.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-71.48</ci_lower_limit>
            <ci_upper_limit>-60.72</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.61</ci_lower_limit>
            <ci_upper_limit>-54.88</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-41.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.18</ci_lower_limit>
            <ci_upper_limit>-36.45</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.04</ci_lower_limit>
            <ci_upper_limit>-44.62</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.69</ci_lower_limit>
            <ci_upper_limit>-44.31</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-41.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.55</ci_lower_limit>
            <ci_upper_limit>-36.13</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Week 12</title>
        <description>LDL-C was measured using ultracentrifugation.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Week 12</title>
          <description>LDL-C was measured using ultracentrifugation.</description>
          <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="79"/>
                <count group_id="O8" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.4"/>
                    <measurement group_id="O2" value="-3.2" spread="3.3"/>
                    <measurement group_id="O3" value="-50.9" spread="3.4"/>
                    <measurement group_id="O4" value="-77.6" spread="3.5"/>
                    <measurement group_id="O5" value="-79.5" spread="3.4"/>
                    <measurement group_id="O6" value="-53.7" spread="3.3"/>
                    <measurement group_id="O7" value="-64.3" spread="3.3"/>
                    <measurement group_id="O8" value="-64.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-79.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-87.0</ci_lower_limit>
            <ci_upper_limit>-71.5</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-77.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-85.2</ci_lower_limit>
            <ci_upper_limit>-69.6</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.5</ci_lower_limit>
            <ci_upper_limit>-43.0</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-61.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.6</ci_lower_limit>
            <ci_upper_limit>-53.7</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-61.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.5</ci_lower_limit>
            <ci_upper_limit>-53.7</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.0</ci_lower_limit>
            <ci_upper_limit>-43.1</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</title>
          <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="79"/>
                <count group_id="O8" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="2.20"/>
                    <measurement group_id="O2" value="-1.26" spread="2.26"/>
                    <measurement group_id="O3" value="-36.23" spread="2.20"/>
                    <measurement group_id="O4" value="-53.21" spread="2.20"/>
                    <measurement group_id="O5" value="-59.19" spread="2.21"/>
                    <measurement group_id="O6" value="-39.05" spread="2.27"/>
                    <measurement group_id="O7" value="-47.05" spread="2.26"/>
                    <measurement group_id="O8" value="-48.83" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-61.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.37</ci_lower_limit>
            <ci_upper_limit>-56.43</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-55.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.37</ci_lower_limit>
            <ci_upper_limit>-50.47</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-38.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.39</ci_lower_limit>
            <ci_upper_limit>-33.48</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.72</ci_lower_limit>
            <ci_upper_limit>-42.44</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.92</ci_lower_limit>
            <ci_upper_limit>-40.67</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.94</ci_lower_limit>
            <ci_upper_limit>-32.65</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
          <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="79"/>
                <count group_id="O8" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.86" spread="2.15"/>
                    <measurement group_id="O2" value="3.22" spread="2.25"/>
                    <measurement group_id="O3" value="-28.88" spread="2.15"/>
                    <measurement group_id="O4" value="-44.29" spread="2.14"/>
                    <measurement group_id="O5" value="-50.59" spread="2.15"/>
                    <measurement group_id="O6" value="-31.16" spread="2.26"/>
                    <measurement group_id="O7" value="-37.55" spread="2.26"/>
                    <measurement group_id="O8" value="-38.81" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.28</ci_lower_limit>
            <ci_upper_limit>-51.61</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.97</ci_lower_limit>
            <ci_upper_limit>-45.33</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.56</ci_lower_limit>
            <ci_upper_limit>-29.92</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-42.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.16</ci_lower_limit>
            <ci_upper_limit>-36.90</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.88</ci_lower_limit>
            <ci_upper_limit>-35.66</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.51</ci_lower_limit>
            <ci_upper_limit>-29.25</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12</title>
          <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="79"/>
                <count group_id="O8" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="1.97"/>
                    <measurement group_id="O2" value="-2.00" spread="1.90"/>
                    <measurement group_id="O3" value="-28.76" spread="1.97"/>
                    <measurement group_id="O4" value="-40.73" spread="1.97"/>
                    <measurement group_id="O5" value="-45.09" spread="1.98"/>
                    <measurement group_id="O6" value="-29.73" spread="1.91"/>
                    <measurement group_id="O7" value="-37.97" spread="1.91"/>
                    <measurement group_id="O8" value="-37.66" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.18</ci_lower_limit>
            <ci_upper_limit>-43.29</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.81</ci_lower_limit>
            <ci_upper_limit>-38.94</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-31.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.83</ci_lower_limit>
            <ci_upper_limit>-26.97</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.99</ci_lower_limit>
            <ci_upper_limit>-31.32</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.29</ci_lower_limit>
            <ci_upper_limit>-31.65</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.06</ci_lower_limit>
            <ci_upper_limit>-23.39</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12</title>
          <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="79"/>
                <count group_id="O8" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="2.13"/>
                    <measurement group_id="O2" value="-0.35" spread="2.38"/>
                    <measurement group_id="O3" value="-35.04" spread="2.13"/>
                    <measurement group_id="O4" value="-47.60" spread="2.12"/>
                    <measurement group_id="O5" value="-53.73" spread="2.14"/>
                    <measurement group_id="O6" value="-34.11" spread="2.40"/>
                    <measurement group_id="O7" value="-42.74" spread="2.39"/>
                    <measurement group_id="O8" value="-43.28" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-53.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.23</ci_lower_limit>
            <ci_upper_limit>-48.65</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.08</ci_lower_limit>
            <ci_upper_limit>-42.52</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.53</ci_lower_limit>
            <ci_upper_limit>-29.97</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-42.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.36</ci_lower_limit>
            <ci_upper_limit>-37.50</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-42.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.81</ci_lower_limit>
            <ci_upper_limit>-36.98</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factors.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-33.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.20</ci_lower_limit>
            <ci_upper_limit>-28.33</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Q4W</title>
          <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Evolocumab 70 mg Q2W</title>
          <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Evolocumab 105 mg Q2W</title>
          <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Evolocumab 280 mg Q4W</title>
          <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Evolocumab 350 mg Q4W</title>
          <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Evolocumab 420 mg Q4W</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

